EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Drug repurposing in autosomal dominant polycystic kidney disease

Julie Xia Zhou, Vicente E Torres

Kidney International · 2023-05 · 103 (5) · 859-871

DOI: 10.1016/j.kint.2023.02.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Kidney International, 2023-05. Verfasst von Julie Xia Zhou und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycys…. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease is characterized by progressive kidney cyst formation that leads to kidney failure. Tolvaptan, a vasopressin 2 receptor antagonist, is the only drug approved to treat patients with autosomal dominant polycystic kidney disease who have rapid disease progression. The use of tolvaptan is limited by reduced tolerability from aquaretic effects and potential hepatotoxicity. Thus, the search for more effective drugs to slow down the progression of autosomal dominant polycystic kidney disease is urgent and challenging. Drug repurposing is a strategy for identifying new clinical indications for approved or investigational medications. Drug repurposing is increasingly becoming an attractive proposition because of its cost-efficiency and time-efficiency and known pharmacokinetic and safety profiles. In this review, we focus on the repurposing approaches to identify suitable drug candidates to treat autosomal dominant polycystic kidney disease and prioritization and implementation of candidates with high probability of success. Identification of drug candidates through understanding of disease pathogenesis and signaling pathways is highlighted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney, Autosomal DominantHumansTolvaptanDrug RepositioningAntidiuretic Hormone Receptor AntagonistsKidney

Stichwörter der Autor:innen

ADPKDdrug repurposingsignaling pathways

Substanzen

TolvaptanAntidiuretic Hormone Receptor Antagonists

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Mayo Clinic Robert M. and Billie Kelley Pirnie Translational Polycystic Kidney Disease Center, Rochester, Minnesota, USA. Electronic addre…

Zitieren

APA

Zhou, J. X., & Torres, V. E. (2023). Drug repurposing in autosomal dominant polycystic kidney disease. Kidney International, 103(5), 859-871. https://doi.org/10.1016/j.kint.2023.02.010

Vancouver

Zhou JX, Torres VE. Drug repurposing in autosomal dominant polycystic kidney disease. Kidney International. 2023;103(5):859-871. doi:10.1016/j.kint.2023.02.010

BibTeX
@article{Zhou2023,
  author = {Zhou, Julie Xia and Torres, Vicente E},
  title = {Drug repurposing in autosomal dominant polycystic kidney disease},
  journal = {Kidney International},
  year = {2023},
  volume = {103},
  number = {5},
  pages = {859--871},
  doi = {10.1016/j.kint.2023.02.010}
}
Kostenlos starten →